These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35130254)

  • 1. The effect of etoricoxib versus diclofenac on blood pressure in hypertensive patients.
    Murtadha Al-Shehristani RM; Aziz ND
    J Pak Med Assoc; 2021 Dec; 71(Suppl 9)(12):S18-S23. PubMed ID: 35130254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP; Curtis SP; FitzGerald GA; Krum H; Kaur A; Bolognese JA; Reicin AS; Bombardier C; Weinblatt ME; van der Heijde D; Erdmann E; Laine L;
    Lancet; 2006 Nov; 368(9549):1771-81. PubMed ID: 17113426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
    Cannon CP; Curtis SP; Bolognese JA; Laine L;
    Am Heart J; 2006 Aug; 152(2):237-45. PubMed ID: 16875903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac.
    Laine L; Curtis SP; Langman M; Jensen DM; Cryer B; Kaur A; Cannon CP
    Gastroenterology; 2008 Nov; 135(5):1517-25. PubMed ID: 18823986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs.
    Krum H; Swergold G; Gammaitoni A; Peloso PM; Smugar SS; Curtis SP; Brater DC; Wang H; Kaur A; Laine L; Weir MR; Cannon CP
    Cardiovasc Ther; 2012 Dec; 30(6):342-50. PubMed ID: 21884017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: results from the MEDAL study.
    Krum H; Swergold G; Curtis SP; Kaur A; Wang H; Smugar SS; Weir MR; Laine L; Brater DC; Cannon CP
    J Hypertens; 2009 Apr; 27(4):886-93. PubMed ID: 19516186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis.
    Zacher J; Feldman D; Gerli R; Scott D; Hou SM; Uebelhart D; Rodger IW; Ozturk ZE;
    Curr Med Res Opin; 2003; 19(8):725-36. PubMed ID: 14687444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
    Krueger K; Lino L; Dore R; Radominski S; Zhang Y; Kaur A; Simpson R; Curtis S
    Ann Rheum Dis; 2008 Mar; 67(3):315-22. PubMed ID: 17965424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative clinical study of the prophylaxis of heterotopic ossifications after total hip arthroplasty using etoricoxib or diclofenac.
    Winkler S; Springorum HR; Vaitl T; Handel M; Barta S; Kehl V; Craiovan B; Grifka J
    Int Orthop; 2016 Apr; 40(4):673-80. PubMed ID: 26728611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perioperative blood loss and gastrointestinal tolerability of etoricoxib and diclofenac in total hip arthroplasty (ETO-DIC study): a single-center, prospective double-blinded randomized controlled trial.
    Winkler SH; Barta S; Kehl V; Schröter C; Wagner F; Grifka J; Springorum HR; Craiovan B
    Curr Med Res Opin; 2016; 32(1):37-47. PubMed ID: 26414653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
    Watson DJ; Bolognese JA; Yu C; Krupa D; Curtis S
    Curr Med Res Opin; 2004 Dec; 20(12):1899-908. PubMed ID: 15701208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of nonsteroidal anti-inflammatory drugs on the indicators of cardiovascular risk in patients with acute nonspecific back pain].
    Zolotovskaya IA; Davydkin IL
    Ter Arkh; 2015; 87(12):18-25. PubMed ID: 26978413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of etoricoxib versus celecoxib and non-selective NSAIDS in the treatment of ankylosing spondylitis.
    Jansen JP; Gaugris S; Choy EH; Ostor A; Nash JT; Stam W
    Pharmacoeconomics; 2010; 28(4):323-44. PubMed ID: 20222755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on the effects of diclofenac sodium and etoricoxib in the treatment of osteoarthritis.
    Ghosh S; Paul S; Das N; Bhattacharyya TK
    J Indian Med Assoc; 2007 May; 105(5):260-2. PubMed ID: 17915794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH; Harper S; Watson DJ; Yu C; Quan H; Lee M; Evans JK; Oxenius B
    Am J Gastroenterol; 2003 Aug; 98(8):1725-33. PubMed ID: 12907325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.
    Zhang S; Zhang Y; Liu P; Zhang W; Ma JL; Wang J
    Clin Rheumatol; 2016 Jan; 35(1):151-8. PubMed ID: 26099603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).
    Combe B; Swergold G; McLay J; McCarthy T; Zerbini C; Emery P; Connors L; Kaur A; Curtis S; Laine L; Cannon CP
    Rheumatology (Oxford); 2009 Apr; 48(4):425-32. PubMed ID: 19223284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
    Baraf HS; Fuentealba C; Greenwald M; Brzezicki J; O'Brien K; Soffer B; Polis A; Bird S; Kaur A; Curtis SP;
    J Rheumatol; 2007 Feb; 34(2):408-20. PubMed ID: 17304660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.